

FOSUN PHARMA
复星医药

2022



1

2

3

4

5

6



1/3

439.52

+12.66% YoY



139.38

+2.49% YoY



30%

25%



31.7%

38.73

+18.17% YoY



42.18

+7.10% YoY



MSCI-ESG

BBB

A

A



[®] **PD-1**
 MSI-H sqNSCLC ES-SCLC SCLC
 FDA EC
 MAA EMA *

[®]
 2022
[®] **CAR-T**
 10

13

III
 mRNA

[®]
 RT002
 III
 SCLC
 Tenapanor NHE3 *



[®]
 Parsabiv[®]

Organon Eurofarma
 Abbott



Syneos Health
 PD-1

Gland
 Pharma
 Cenexi
CDMO
 Sisram

66%



GT1-GT6

CMC

Scientific Advisor
Board

SAB

5

®

2022

674

	2021	2022	YoY
	390.11	439.52	12.7%
	47.29	37.31	-21.1%
	32.77	38.73	18.2%
	39.38	42.18	7.1%
	49.78	58.85	18.2%
	38.37	43.02	12.1%
	1.85	1.43	-22.7%
()	30%	30%	-

BNTX -1.42 15.93 , BNTX
-10 37.31
21.10%

	2021	2022
	48.1%	47.3%
	23.3%	20.9%
	8.3%	8.7%
	9.8%	9.8%
	1.2%	1.5%
	24.8%	26.4%


1
2)
3
2.96
1
2
3

	2021	2022
	103.17	162.41
	391.96	445.82
	1.04	1.06
	0.85	0.85
	48.2%	49.5%

2022 7 A
44.8 1
3 2
A



—




1
2
3
4

BNTX

2022

2021







/ADC RNA



“

ADC “




RNAi

mRNA



“ CAR-



&



CNS



“ ”

50%

FIC+BIC

—



MSI-H ® PD-1

® CAR-T

® CD20

® HER2

®

®


®

&





1/2



2/2




&

&BD&

:

, &BD



MSCI-ESG

A

2022

BBB
2021

BB
2020



Environment

EHS		EHS		EHS
2021-2026		EHS		
2022		115.36		
	337,806			3.2%



Social




A



-

1

2



RNA

/ADC

55.22 26%¹
+39.44% YoY


® HER2 ®
TNF- ® ®
PD-1 ®

YoY **50.97** +13.62%
85%

16.54%
11.53% 35.52

30%

260 2022
249
16 PCT 17
48





SCLC

PD-1

3.4

2022

9



PD-1

MSI-H

SCLC FDA EC



ES-SCLC

III

(OS)

OS

15.4

10.9

24

43.1%

7.9%

JAMA

Nature Medicine

British Journal of Cancer




27

110

30%

400

DTP




2022

10	5	mRNA	
		® HER2	
		® CD20	
		®	
5	10	3	®
			®
3	5	8	® PD-1
			®
			®
			VERO
			8
1	3	31	® TNF-
			®
			®
			®
			31







2022



2022



CBD+Professional Skincare Solution



2017

2019

2020

2021

2022

200

800

31.2

2016

2017

Xi

Intuitive Surgical

“ ”

1,700

4,000



2022

55

300

10

2000

FDA

7,544

2022 12 31

55,000

1,000

Ion

2019 Ion




FDA

2021 10 Ion

Ion



2022







2011-2017



2018-2020



2021



6,333 *



JCI

“

”

JVF



JCI国际认证医院
Organization Accredited
by Joint Commission International

2022

21.45

1,750

1.11

86.47%



深圳恒生医院
SHENZHEN HENGSHENG HOSPITAL

2017 11
60%

9.09

600



900

2022 1


70%


800



上海复星医疗旗下高品质医院
医保定点医院

—






		4,066	4.27%
“	”		
	1,209	11.77%	
	330	13.49%	



1/2



2/2

		/			IND	1	2	3	NDA
	FS-1502	HER2	HER2						
	FS-1502+	HER2+PD-1	HER2						
	HLX14	¹  ORGANON	RANKL						
	HLX26		LAG-3						
	HLX35 ²	 BINACEA	EGFR×4-1BB		2022 1 NMPA	2022 6			
	HLX301		PD-L1×TIGIT		2022 2	2022 3 NMPA		7	
	HLX15		CD38						
	HLX13		CTLA-4						
			EPO						
			INSR						
		50R	INSR						
			GLP-1						
	RT002		GL						
			CD		2022 1			Ñ	%

- 1 Organon
- 2 Binacea

3

2023 2 28

1/2

		I			IND	1	2	3	NDA
FCN-437c	CDK4/6	(1L)			2022	1	NMPA	III	I
		(2L)			2022	1		III	
SAF-189	ALK				2022	1	NMPA	III	I
	ROS1								
HLX-208	BRAF V600E		LCH	ECD	2022	1	NMPA	IIb/II	
FCN-159	MEK	I							
					2022	5	NMPA		
					2022	5	NMPA		
YP01001	VEGFR								
FCN-338	BCL-2								
		B							
FH-2001	FGFR/PD-L1								

2/2

		I			IND	1	2	3	NDA
		TPO-R	ITP	2022 12 NDA NMPA					
	Tenapanor	NHE 3	(ESRD-HD)						
		-							
	Tenapanor	NHE 3	(IBS-C)	I					
	FCN-342	URAT1							
	Molnupiravir	RNA							
	Paxlovid	3CL							
	BNT162b2	-		EUA					
	PA-824	-	/ MDR-TB XDR-TB	Pretomanid*					
	Opicapone	COMT		Ongentys*					
	Fortacin	-		*					
	ET-26	-		2022 7 II					

2023 2 28

“

“

”

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun ” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com